Deslandres M, Sibaud V, Chevreau C, Delord J P
Institut Claudius Regaud, Centre de Lutte Contre le Cancer, Département d''ncologie Médicale, 20-24 rue du pont Saint Pierre 31052 Toulouse, France.
Ann Dermatol Venereol. 2008 Jan;Spec No 1:16-24. doi: 10.1016/S0151-9638(08)70093-0.
Basic knowledge in oncogenesis has dramatically improved in the last decade providing more recently new drugs for cancer treatment. These new targeted compounds usually act by inhibiting tyrosine kinase activity of one or more than one proteins involved in tumor growth and cancer progression. This pharmacological effect is the result of monoclonal or small molecule action. Many of these new compounds have cutaneus secondary effects. Cancer patients are now facing new toxicity, essentially skin toxicity. The cutaneous side effects observed in the patients depend on the drug. For example, EGFR inhibitors induce acneiform rash whereas multitarget tyrosine kinase inhibitors induce different more complex effects which physiopatholgy is not yet completely understood. The secondary effects that are frequently observed are described is this article. A better clinical long term management of these effects is a clear medical need as of these effects could be surrogate markers of drug efficacy.
在过去十年中，肿瘤发生的基础知识有了显著进步，最近为癌症治疗提供了新的药物。这些新的靶向化合物通常通过抑制一种或多种参与肿瘤生长和癌症进展的蛋白质的酪氨酸激酶活性来发挥作用。这种药理作用是单克隆或小分子作用的结果。这些新化合物中的许多都有皮肤副作用。癌症患者现在面临新的毒性，主要是皮肤毒性。患者中观察到的皮肤副作用取决于药物。例如，表皮生长因子受体（EGFR）抑制剂会诱发痤疮样皮疹，而多靶点酪氨酸激酶抑制剂会诱发不同的、更复杂的效应，其病理生理学尚未完全了解。本文描述了经常观察到的副作用。对这些效应进行更好的临床长期管理是一项明确的医疗需求，因为这些效应可能是药物疗效的替代标志物。
